Summary
In the developing pancreas, transient Neurog3-expressing progenitors give rise to four major islet-cell types, α, β, δ, and γ; when and how the Neurog3+ cells choose cell-fate is unknown. Using single-cell RNAseq, trajectory analysis, and combinatorial lineage tracing, we showed here that the Neurog3+ cells co-expressing Myt1 (i.e., Myt1+Neurog3+) were biased towards β-cell fate; while those not simultaneously expressing Myt1 (Myt1-Neurog3+) favored α-fate. Myt1 manipulation only marginally affected α- vs. β-cell specification, suggesting Myt1 as a marker but not determinant for islet-cell type specification. The Myt1+Neurog3+ cells displayed higher Dnmt1 expression and enhancer methylation at Arx, an α-fate-promoting gene. Inhibiting Dnmts in pancreatic progenitors promoted α-cell specification, while Dnmt1 over-expression or Arx enhancer hyper-methylation favored β-cell production. Moreover, the pancreatic progenitors contained distinct Arx enhancer methylation states without transcriptionally definable sub-populations, a phenotype independent of Neurog3 activity. These data suggest that Neurog3-independent methylation on fate-determining gene-enhancers specifies distinct endocrine-cell programs.